INT164325

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 1.88
Pain Relevance 1.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Abcg2) ATPase activity (Abcg2) plasma membrane (Abcg2)
nucleus (Abcg2)
Anatomy Link Frequency
MCF-7 3
Abcg2 (Mus musculus)
Pain Link Frequency Relevance Heat
dexamethasone 21 99.98 Very High Very High Very High
cINOD 4 96.72 Very High Very High Very High
Bioavailability 11 66.96 Quite High
Paracetamol 4 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Glutamate 2 5.00 Very Low Very Low Very Low
Potency 2 5.00 Very Low Very Low Very Low
corticosteroid 1 5.00 Very Low Very Low Very Low
fluoxetine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 19 98.72 Very High Very High Very High
Drug Induced Neurotoxicity 1 98.04 Very High Very High Very High
INFLAMMATION 5 96.52 Very High Very High Very High
Toxicity 17 83.92 Quite High
Cancer 21 77.92 Quite High
Myeloid Leukemia 86 58.64 Quite High
Primary Sclerosing Cholangitis 3 53.12 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 1 50.24 Quite High
Leukemia 15 50.00 Quite Low
Disease 24 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Interestingly, imatinib is both a substrate and an inhibitor of BCRP (Burger et al 2004; Houghton et al 2004).
Negative_regulation (inhibitor) of BCRP
1) Confidence 0.39 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.20 Pain Relevance 0.03
The level of BCRP protein, expressed as a ratio of the corresponding control, was decreased in dexamethasone-treated MCF-7/MX cells.
Negative_regulation (decreased) of BCRP in MCF-7 associated with dexamethasone
2) Confidence 0.21 Published 2009 Journal Oncol. Res. Section Abstract Doc Link 19911699 Disease Relevance 0.32 Pain Relevance 0.29
The fungal toxin, fumitremorgin C (FTC), is a strong inhibitor of BCRP but its use in vivo has been limited due to its neurotoxicity [196].
Negative_regulation (inhibitor) of BCRP associated with drug induced neurotoxicity
3) Confidence 0.18 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC1277830 Disease Relevance 0.31 Pain Relevance 0
Dexamethasone showed a dose-independent and a time-dependent effect on decreasing the mRNA level of BCRP gene in comparison with control in MCF-7 and MCF-7/MX breast cancer cell lines, whereas no changes were noted in the presence of indomethacin.
Negative_regulation (decreasing) of BCRP in MCF-7 associated with breast cancer and dexamethasone
4) Confidence 0.15 Published 2009 Journal Oncol. Res. Section Abstract Doc Link 19911699 Disease Relevance 0.34 Pain Relevance 0.29
Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines.
Negative_regulation (downregulates) of BCRP associated with breast cancer and dexamethasone
5) Confidence 0.15 Published 2009 Journal Oncol. Res. Section Title Doc Link 19911699 Disease Relevance 0.37 Pain Relevance 0.30
Dexamethasone showed a dose-independent and a time-dependent effect on decreasing the mRNA level of BCRP gene in comparison with control in MCF-7 and MCF-7/MX breast cancer cell lines, whereas no changes were noted in the presence of indomethacin.
Negative_regulation (decreasing) of BCRP in MCF-7 associated with breast cancer and dexamethasone
6) Confidence 0.05 Published 2009 Journal Oncol. Res. Section Abstract Doc Link 19911699 Disease Relevance 0.34 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox